Abstract
This is a retrospective, multicenter study to evaluate biological features and outcome of elderly patients diagnosed with acute lymphoblastic leukemia (ALL) during the last 10 years in ten hematological centers in Poland. Eighty-seven patients aged 60 years or older were studied. To our knowledge, this is one of the largest group of elderly patients with ALL evaluated. We have not observed differences in immunological subtypes and Ph chromosome incidence as compared with younger adult ALL presented in the literature. Induction chemotherapy was administered in 75 patients. We observed complete remission (CR) in 34 (45%, 95% CI: 33–56%) patients. Induction death occurred in 11 (15%) patients. Thirty patients (40%) showed primary resistance to chemotherapy. Median overall survival (OS) of all patients was 150 days. Median disease-free survival (DFS) of responding patients was 180 days. We observed four long-term survivors (DFS longer than 3 years) in our group of patients. Factors influencing OS were CR achievement, female gender, and WBC below 30×109/l. Male gender was the only prognostic factor negatively affecting probability to achieve CR. We have not observed any differences in either biology or outcome between patients aged 60–69 years and those aged more than 70 years. ALL of the elderly is a rare disease with poor prognosis. Further clinical trials evaluating the disease features, outcome, and new therapeutic approaches are warranted.
Similar content being viewed by others
References
Annino L, Goekbugot N, Delannoy A (2002) Acute lymphoblastic leukemia in the elderly. Hematol J 3:219–223
Baker MA (1987) The management of leukemia in the elderly. Baillieres Clin Haematol 1:427–448
Bassan R, Di Bona ET, Lerede E, Pogliani G, Rossi A, D’Emilio M, Buelli A, Rambaldi P, Viero E, Rodeghiero T, Barbui P (1996) Aged-adapted moderate dose induction and flexible outpatient post remission therapy for elderly patient with acute lymphoblastic leukemia. Leuk Lymphoma 22:295–301
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1978) Proposals for the classification of the acute leukemias. Br J Haematol 33:451–458
Boucheix C, David B, Sebban C, Racadot E, Bene MC, Bernard A, Campos L, Jouault H, Sigaux F, Lepage E, Herve P, Fiere D for French Group on Therapy for Adult Acute Lymphoblastic Leukemia (1994) Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters and outcome: an analysis of a prospective trial including 562 tested patients (LALA 87). Blood 84:1603–1612
Cartwright RA, Gurney KA, Moorman AV (2002) Sex ratios and the risks of haematological malignancies. Br J Haematol 118:1071–1077
Chessells JM, Richrds SM, Bailey CC, Lilleyman JS, Eden OB (1995) Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRCUKALL trials. Br J Haematol 89:364–372
Colovic M, Bogdanovic A, Jankovic G, Kraguljac N, Suvajdzic N (2003) Long-term survival in acute lymphoblastic leukaemia in adults treated according to the LALA 87 protocol. Chemotherapy 49:138–145
Delannoy A, Cazin B, Thomas X, Bouabdallah R, Boiron JM, Huguet F, Straetmans N, Zerazhi H, Vernant JP, Dombret H, Bilhou-Nabera C, Charrin C, Boucheix C, Sebban C, Lheritier V, Fiere D (2002) Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of interferon alpha given as a single agent after complete remission. Leuk Lymphoma 43:75–81
Delannoy A, Ferrant A, Bosly A, Chatelain C, Martiat P, Michaux JL, Sokal G (1990) Acute lymphoblastic leukemia in the elderly. Eur J Haematol 45:90–93
Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, Fenaux P (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood 100:2357–2366
Donadieu J, Auclerc MF, Baruchel A, Lablanc T, Landman-Parker J, Perel Y, Michel G, Cornu G, Bordigoni P, Sommelet D, Leverger G, Hill C, Schaison G for the Fralle Group (1998) Critical study of prognostic factors in childhood acute lymphoblastic leukemia: differences in outcome are poorly explained by the most significant prognostic variables. Br J Haematol 102:729–739
Duffy DR, Santner TJ (1987) Confidence intervals for binomial parameter based on multistage tests. Biometrics 43:81–93
Durrant IJ, Richards SM, Prentice HG, Goldstone AH (2000) The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am 14:1327–1352
Ellison R, Holland JF, Weil M (1968) Arosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32:507–523
Ellison R, Mick R, Cuttner J, Schiffer CA, Silver RT, Enderson ES, Woliver T, Royston I, Davey FR, Glicksman AS, Bloomfield CD, Holland JF (1991) The effect of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphoblastic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group. Br J Clin Oncol 9:2002–2015
Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, Albitar M, Estrov Z (2000) Outcome of Philadelphia-chromosome positive adult acute lymphoblastic leukemia. Leuk Lymphoma 36:263–273
Ferrari A, Aunino L, Crescenzi S, Romani C, Mandelli F (1995) Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25 years period. Leukemia 9:1643–1647
Goekbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, Maschmeyer G, Rieder H, Weiss A, Thiel E, Messerer D (2001) Subtypes and treatment outcome in adult acute lymphoblastic leukemia (ALL) >55 years. Hematol J 1 [Suppl 1]:186
Imbach P, Fuchs A, Berchtold W, Arnet B, Stupnicki A, Angst R, Singer E (1995) Boys but not girls with T-lineage acute lymphocytic leukemia (ALL) are different from children with B-progenitor ALL. Population-based data results of initial prognostic factors and long-term event-free survival. Swiss Pediatric Oncology Group. J Pediatr Hematol Oncol 17:346–349
Kantarjian HM, O’Brien S, Smith T, Estey EH, Beran M, Preti A, Pierce S, Keating MJ (1994) Acute lymphoblastic leukemia in the elderly: characteristics and outcome with the vincristine adriamycin dexamethasone (VAD) regimen. Br J Haematol 88:94–100
Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M (2000) Results of treatment with hyper CVAD a dose intensive regimen in adult acute lymphocytic leukemia. J Clin Oncol 18:547–561
Kaplan ER, Meier P (1958) Non-parametric estimation from in complete observations. J Am Stat Assoc 53:457–481
Larson LA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ (1998) A randomized control trial of Filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 92:1556–1564
Legrand O, Marie JP, Marjanovic Z, Cadiou M, Blanc C, Ramond S, Viguie F, Perrot JY, Zittoun R (1997) Prognostic factors in elderly acute lymphoblastic leukemia. Br J Haematol 97:596–602
Offidani M, Corvatta L, Centurioni L, Leoni F, Materba L, Mele A, Marconi M, Scortechini A, Masia AC, Leoni P (2003) High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. Hematol J 4:47–53
Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll AJ, Land V, Look AT, McIntyre B, Camitta B (1999) Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 13:1696–1707
Sorensen JT, Gerald K, Bodewsteiner D, Holmes FF (1993) Effect of age on survival in acute leukemia 1950–1990. Cancer 72:1602–1606
Taylor PRA, Reid M.M., Bown N, Hamilton PJ, Proctor SJ (1992) Acute lymphoblastic leukemia in patients aged 60 years and over: a population based study of incidence and outcome. Blood 80:1813–1817
Taylor PRA, Reid MM, Proctor SJ (1994) Acute lymphoblastic leukemia in the elderly. Leuk Lymphoma 13:373–380
Thomas X, Danaila C, Le Q-H, Sebban C, Troncy J, Charrin C, Lheritier V, Michallet M, Magaud JP, Fiere D (2001) Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia : a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 15:1811–1822
Thomas X, Olteanu N, Charrin C, Lheritier V, Magand JP, Fiere D (2001) Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol 67:73–83
Virgilio JF, Moscinski LC, Ballester OF, Corrado C, Guida C, Guida C, Balducci L, Saba H (1993) Acute lymphocytic leukemia (ALL) in elderly patients Hematol Oncol 11:121–126
Whitecar JP, Bodey GP, Freireich EJ (1972) Cyclophosphamide, vincristine, arabinoside cytosine and prednisone (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep 56:43–54
Acknowledgements
The following members of the Polish Adult Leukemia Group (PALG) are also authors of this publication: I. Seferyńska MD PhD (Warsaw), M. Całbecka MD, PhD, (Toruń), L. Konopka MD, PhD (Warsaw), K. Zawilska MD, PhD (Poznań). This work was supported in part by a grant from the Medical University of Lodz no. 503-106-2.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Robak, T., Szmigielska-Kapłon, A., Wrzesień-Kuś, A. et al. Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience. Ann Hematol 83, 225–231 (2004). https://doi.org/10.1007/s00277-003-0808-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-003-0808-9